| Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. | |
| | |
MedLine Citation:
|
PMID: 19450720 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The prevalence of heart failure (HF) is high and still on the rise. In 2004, an estimated 5.2 million adults in the United States carried the diagnosis of HF with a mortality rate of >19%. The incidence of HF is higher in individuals 65 years or older. As the US population grows older, the personal and economic costs of this disease are expected to grow. More than 75% of patients with HF have a history of hypertension, and blood pressure control can reduce the risk of serious cardiovascular events and death in this population. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system can reduce the negative effects of chronic renin-angiotensin-aldosterone system activation on the progression of HF. This review discusses the clinical data supporting the use of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers, alone or in combination, for improving outcomes in patients with HF. |
| | |
Authors:
|
Alan H Gradman; Vasilios Papademetriou |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: American heart journal Volume: 157 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-19 Completed Date: 2009-11-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: S17-23 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiovascular Diseases, The Western Pennsylvania Hospital, Pittsburgh, PA15224-1722, USA. gradmanmd@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers / administration & dosage Angiotensin-Converting Enzyme Inhibitors / administration & dosage* Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Heart Failure, Systolic / diagnosis, drug therapy*, etiology*, mortality Humans Male Prognosis Randomized Controlled Trials as Topic Receptors, Angiotensin / administration & dosage, antagonists & inhibitors* Renin-Angiotensin System / drug effects*, physiology Risk Assessment Severity of Illness Index Survival Rate Treatment Outcome Ventricular Dysfunction, Left / complications*, diagnosis, mortality |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Receptors, Angiotensin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of alcohol consumption on bone mineral density and hormonal parameters in physically active m...
Next Document: Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic even...